Johnson & Johnson
JNJleaderJohnson & Johnson is a global healthcare company operating in pharmaceuticals and medical devices. Following the spin-off of its consumer health division as Kenvue, it focuses on innovative medicine and MedTech.
Productos e Ingresos
Participación de Ingresos por Producto
Desglose de Ingresos ($85.2B)
Datos estáticos (cargando finanzas en tiempo real…)
Composición de segmentos y clientes principales
Detalles del producto
Pharmaceutical products including immunology, oncology, and neuroscience therapeutics
Surgical instruments, robotics, and interventional solutions
Joint reconstruction, spine, and sports medicine implants
Relaciones en la Cadena de Suministro
Contexto macro y de mercado
메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요
미국 헬스케어 지출 (2026E)
AI 진단 정확도 개선
UNH 의료손해율
약가 협상 대상 의약품
Próximos catalizadores
Señales Institucionales
| Institución | Acción | Valor | Trimestre | Fecha de presentación |
|---|---|---|---|---|
| BlackRock | accumulating | $923M | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $384M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $358M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $25M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $50M | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $948M | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $431M | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $10.9B | 2024.06 | 2024-08-13↑ |
| BlackRock | accumulating | $7.7B | 2024.06 | 2024-08-13↑ |
| BlackRock | accumulating | $714M | 2024.06 | 2024-08-13↑ |
| BlackRock | accumulating | $1.2B | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $509M | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $870M | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $27M | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $2.5B | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $137M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $41M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $515M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $80M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $17M | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $531M | 2024.06 | 2024-08-13↑ |
| Vanguard Group | accumulating | $1.1B | 2025.12 | 2026-01-29↑ |
| Vanguard Group | accumulating | $222M | 2025.12 | 2026-01-29↑ |
| Vanguard Group | accumulating | $44.8B | 2025.12 | 2026-01-29↑ |
| Vanguard Group | accumulating | $2.8B | 2025.12 | 2026-01-29↑ |
| Vanguard Group | accumulating | $828M | 2025.12 | 2026-01-29↑ |
| Vanguard Group | reducing | $11K | 2025.12 | 2026-01-29↓ |
| Vanguard Group | accumulating | $4M | 2025.12 | 2026-01-29↑ |
| State Street | accumulating | $27.7B | 2025.12 | 2026-02-13↑ |
| Wellington Management | accumulating | $4.7B | 2025.12 | 2026-02-17↑ |
| Wellington Management | accumulating | $36M | 2025.12 | 2026-02-17↑ |
| Wellington Management | reducing | $6M | 2025.12 | 2026-02-17↓ |
| Wellington Management | reducing | $2M | 2025.12 | 2026-02-17↓ |
| Wellington Management | reducing | $2M | 2025.12 | 2026-02-17↓ |
| Wellington Management | reducing | $14M | 2025.12 | 2026-02-17↓ |
| Wellington Management | accumulating | $53M | 2025.12 | 2026-02-17↑ |
| Wellington Management | accumulating | $27M | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | accumulating | $2.2B | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | reducing | $509K | 2025.12 | 2026-02-17↓ |
| FMR (Fidelity) | accumulating | $19M | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | accumulating | $1.3B | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | accumulating | $43M | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | accumulating | $386M | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | accumulating | $14M | 2025.12 | 2026-02-17↑ |
Últimas noticias
Análisis IA
Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de Johnson & Johnson impulsado por IA.
Información de la Empresa
Estado del sector — 헬스케어
Noticias del sector메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요
미국 헬스케어 지출 (2026E)
AI 진단 정확도 개선
UNH 의료손해율
약가 협상 대상 의약품
Temas clave
- •CMS 메디케어 어드밴티지 수가 인하 → 보험사 마진 압박
- •AI 영상진단·병리학 도입 가속 — Tempus, Veracyte 수혜
- •GLP-1 보험 적용 확대 논의 → UNH·CVS 비용 증가 리스크
Próximos catalizadores
- ◆CMS 메디케어 최종 수가 발표 (2026.Q2)
- ◆UNH/HUM/CVS Q1 실적 (2026.04)